Please login to the form below

Not currently logged in
Email:
Password:

PDL BioPharma CEO will quit despite being cleared of misconduct

US-based biopharmaceutical company PDL BioPharma has revealed that Mark McDade will quit his position as CEO of the company by the end of 2007 for personal reasons, despite being cleared in an internal company investigation into accusations of improper personal conduct and breach of fiduciary duty.

US-based biopharmaceutical company PDL BioPharma has revealed that Mark McDade will quit his position as CEO of the company by the end of 2007 for personal reasons, despite being cleared in an internal company investigation into accusations of improper personal conduct and breach of fiduciary duty.

The original investigation examined an alleged relationship between McDade and another company officer that was said to create a conflict of interest. It also probed allegations that McDade had kept information about another company interested in buying PDL from the board of directors.

The company said its board audit committee, assisted by two independent law firms, concluded that the evidence did not support either allegation.

PDL's chairman, Patrick Gage, will take the job of executive chairman until a new CEO is appointed. Gage has been on the company's board since 2003.

The companys largest shareholder, Third Point LLC, had lobbied for McDades to be fired, accusing him of failing to close a potential deal with a large pharmaceutical company, and adding that the company missed earnings and sales projections.

In April 2007, PDL's chairman and director Max Link resigned as chairman in what was termed by the company as a mutual decision to avoid a conflict of interest regarding PDLs litigation with Alexion Pharmaceuticals.

Link is chairman of Alexion, while PDL has filed a patent infringement lawsuit against the company.

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics